Astellas Pharma has abandoned the development of its oral direct factor Xa inhibitor darexaban. The Japanese firm blamed both the …
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership

